LIVE Webinar: Finding the Right AML Treatment for Me

December 11, 2017

What is personalized medicine, and how can it help acute myeloid leukemia (AML) patients? Find out during this live AML webinar on Monday, December 11 at 2:30 PM ET, 11:30 AM PT, 1:30 PM CT, in partnership with the Patient Empowerment Network and The Leukemia & Lymphoma Society (LLS). We’ll be broadcasting from the annual American Society of Hematology (ASH) meeting, so register now to watch live or get access to the replay afterwards.

During the webinar, you’ll hear a panel of experts give an overview of the AML news coming out of ASH, personalized medicine options available and more. There will also be a question-and-answer session, so send in your questions now to

Join us to learn about:

  •       Approved and promising personalized medicine approaches for AML patients
  •       How to access a clinical trial that’s right for you
  •       The current limitations of personalized medicine

Once you register, you will receive a confirmation email with details for joining the program at the scheduled time.

Host & Guests

Host, Patient Power Co-Founder, CLL Patient and Advocate


Laurence Joseph Dineen Chair in Leukemia Research

Memorial Sloan Kettering Cancer Center

Executive Vice President, Chief Medical Officer

AML Patient Advocate

Register Now

I understand that the information I've provided will only be accessed by Patient Power, LLC and its contracted third parties to mail (and email) helpful information about cancer and related products and services. Patient Power will not sell or transfer my name or contact information to any third party for their marketing use.

Log in    Already a member? Log in now.

Community Member Account

Help us to better understand you

Stay Informed

Can't read the security code? Refresh Code

If you are having issues with the registration form, please call (888) 739-3127 to register over the phone.

This is a Patient Empowerment Network program produced by Patient Power, in partnership with The Leukemia & Lymphoma Society (LLS). We thank Astellas, Celgene Corporation, Novartis, Pfizer and Seattle Genetics for their support.

Page last updated on November 21, 2017